{
    "clinical_study": {
        "@rank": "124483", 
        "arm_group": [
            {
                "arm_group_label": "Octaplas\u2122", 
                "description": "Patients treated with Octaplas\u2122 infusion solution for IV administration as prescribed by their treating physician."
            }, 
            {
                "arm_group_label": "Plasma", 
                "description": "Patients treated with regular plasma (e.g., fresh frozen plasma (FFP) and other FDA and American Association of Blood Banks (AABB) approved plasma products)."
            }
        ], 
        "brief_summary": {
            "textblock": "Post-Marketing Requirement study to evaluate the safety of octaplas\u2122 versus plasma in\n      patients undergoing orthotopic liver transplantation (OLT).  The primary objective is to\n      assess the incidence of hyperfibrinolysis in patients undergoing (OLT) receiving octaplas\u2122\n      versus regular plasma (e.g., fresh frozen plasma and other FDA and AABB approved plasma\n      products)."
        }, 
        "brief_title": "Post-Marketing Requirement to Evaluate the Safety of Octaplas\u2122 Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation With Special Emphasis on Hyperfibrinolysis.", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Coagulopathy", 
            "Endstage Liver Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Blood Coagulation Disorders", 
                "Hemostatic Disorders", 
                "Liver Diseases", 
                "End Stage Liver Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female age \u226518 years\n\n          -  Patient is scheduled to undego orthotopic liver transplantation (OLT)\n\n          -  Patient has a natural MAYO End-Stage Liver Disease (MELD) score of 15-40\n\n          -  Patient is willing to give voluntary written informed consent before any study-\n             related procedure is to be performed that is not part of standard medical\n             care, with the understanding that consent may be withdrawn by the subject at any time\n             without prejudicing future medical care\n\n        Exclusion Criteria:\n\n          -  Patient has a history of severe hypersensitivity reaction to plasma-derived products\n             or to any excipient of the investigational product\n\n          -  Patient is known to be IgA deficient with documented antibodies against IgA\n\n          -  Patient is a planned recipient for a living donor OLT\n\n          -  Patient has a severe deficiency of Protein S\n\n          -  Patient is currently participating in an interventional clinical study or has\n             participated in one within 30 days of the date of their OLT"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Study population will include patients undergoing orthotopic liver transplantation"
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02037373", 
            "org_study_id": "LAS-215"
        }, 
        "intervention": [
            {
                "arm_group_label": "Octaplas\u2122", 
                "description": "Octaplas\u2122 infusion solution for IV administration as prescribed by the treating physician.", 
                "intervention_name": "Octaplas\u2122", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Plasma", 
                "description": "Plasma as prescribed by the treating physician.", 
                "intervention_name": "Plasma", 
                "intervention_type": "Biological", 
                "other_name": "FFP and other approved plasma products"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "intra and post-op coagulopathy in patients undergoing OLT", 
        "lastchanged_date": "April 29, 2014", 
        "number_of_groups": "2", 
        "official_title": "Post-Marketing Requirement Study to Evaluate the Safety of Octaplas\u2122 Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation With Special Emphasis on Hyperfibrinolysis.", 
        "overall_contact": {
            "email": "Michael.Eppolito@octapharma.com", 
            "last_name": "Michael Eppolito, MBA", 
            "phone": "215-527-4374"
        }, 
        "overall_official": {
            "affiliation": "International Medical Monitor", 
            "last_name": "Wolfgang Frenzel", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The incidence of 'clinically relevant hyperfibrinolytic events' in patients receiving octaplas\u2122 will be compared with the incidence rate in patients receiving plasma. For this trial a 'clinically relevant hyperfibrinolytic event' is defined as a decrease of at least 7.5% in the maximum amplitude (MA) as measured by the thromboelastography (TEG) or rotational thromboelastography (ROTEM) within 30 minutes after MA is achieved and the event is associated with bleeding requiring intervention.", 
            "measure": "To assess the incidence of hyperfibinolysis in patients undergoing OLT receiving octaplas\u2122 versus regular plasma (e.g., fresh frozen plasma (FFP) and other FDA and American Association of Blood Banks (AABB) approved plasma products).", 
            "safety_issue": "No", 
            "time_frame": "3 days (perioperative period plus post-operative follow-up)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02037373"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The incidence of all adverse drug reactions (i.e., transfusion reactions) during the study period among patients receiving octaplas\u2122 in comparison to standard plasma products.", 
            "measure": "The safety of octaplas\u2122 in comparison to plasma will be assessed by monitoring the occurrence of adverse drug reactions (i.e., transfusion reactions).", 
            "safety_issue": "Yes", 
            "time_frame": "3 days (perioperative period plus post-operative follow-up)"
        }, 
        "source": "Octapharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Octapharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}